Takeda Sheds More Non-Core Assets, Employees In $670m Orifarm Deal
Danish firm picks up portfolio and manufacturing sites, along with around 600 employees.
You may also be interested in...
Japanese major presses on with post-Shire divestments even after passing strategic target.
A year after inking a multi-billion dollar deal to get hold of the Takeda eye drop, Novartis has given up on getting approval for Xiidra in Europe with the EMA unconvinced about the therapy's efficacy.
While it has seen no coronavirus-related business impact so far and uncertainties remain, Takeda expects lower costs related to the Shire acquisition to propel its profits this fiscal year.